Announcement PDF 19 October 2023 Not for release to US wire services or distribution in the United States Dear Optionholder, NOTIFICATION TO OPTIONHOLDERS We are writing to you in relation to your option holding in Microba Life Sciences Limited (ASX:MAP) ("Microba" or "the Company"). On 19 October 2023, Microba announced the launch of a A$20.0 million pro rata accelerated non-renounceable entitlement offer (Entitlement Offer) of new fully paid ordinary shares (Entitlement Offer Shares) at an offer price of A$0.23 per Entitlement Offer Share (Offer Price). The Entitlement Offer is comprised of an offer of 1 Entitlement Offer Share for every 4 shares to raise gross proceeds of up to A$20.0 million. The retail component of the Entitlement Offer (Retail Entitlement Offer) will be made to shareholders with a registered address in Australia or New Zealand at 7.00pm on the record date of Monday, 23 October 2023 (Record Date). A retail offer booklet will be dispatched to eligible retail shareholders (Eligible Retail Shareholders) on Thursday, 26 October 2023. The Entitlement Offer is being made without a prospectus or disclosure document in accordance with section 708AA of the Corporations Act 2001 (Cth) as modified by ASIC Corporations (Non-Traditional Rights Issues) Instrument 2016/84. The Entitlement Offer is being made pursuant to an offer booklet for the Retail Entitlement Offer (Retail Offer Booklet) to be issued to eligible shareholders on or around Thursday, 26 October 2023 which is available on the ASX website at www.asx.com.au. Optionholders The Company is giving you notice that as an optionholder of the Company, if you wish to participate in the Entitlement Offer with respect to your options (Options), you must exercise your Options before the Record Date. If you require an option exercise form, please email the Joint Company Secretary, Peter Webse, Peter.Webse@microba.com. There is no obligation for you to exercise your Options. This letter is intended to inform you of your rights in relation to your Options and the Entitlement Offer. If you do not wish to participate in the Entitlement Offer you do not need to take any action. Questions If you have any queries about the Entitlement Offer, please contact Automic Group on 1300 288 664 (within Australia) or +61 2 9698 5414 (outside Australia) between 8:30am and 5:00pm (Sydney time), Monday to Friday during the offer period. Dr Luke Reid Chief Executive Officer E: Luke.Reid@microba.com Authorised for release by the Board Microba Life Sciences Ltd ABN 82 617 096 652 Level 10, 324 Queen Street, Brisbane QLD 4000 Australia T: 1300 974 621 E: investor@microba.com W: microba.com About Microba Life Sciences Limited Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions. Disclaimer Forward looking statements This document contains certain "forward-looking statements". The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this document are based on assumptions and contingencies that are subject to change without notice and involve known and unknown risks and uncertainties and other factors that are beyond the control of Microba, its directors and management. This includes statements about market and industry trends, which are based on interpretations of current market conditions. Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based. These statements may assume the success of Microba’s business strategies. The success of any of those strategies will be realised in the period for which the forward-looking statement may have been prepared or otherwise. Readers are cautioned not to place undue reliance on forward-looking statements and except as required by law or regulation, none of Microba, its representatives or advisers assumes any obligation to update these forward-looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this document. The forward-looking statements are based on information available to Microba as at the date of this document. Except as required by law or regulation (including the ASX Listing Rules), none of Microba, its representatives or advisers undertakes any obligation to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forwardlooking statements. Not an offer in the United States This document has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or in any other jurisdiction in which such an offer would be illegal. Any securities described in this document have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the “US Securities Act”) or the securities laws of any state or jurisdiction of the United States. Accordingly, the securities described in this document may not be offered or sold, directly or indirectly, in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act and applicable securities laws of any state or other jurisdiction of the United States Microba Life Sciences Ltd ABN 82 617 096 652 Level 10, 324 Queen Street, Brisbane QLD 4000 Australia T: 1300 974 621 E: investor@microba.com W: microba.com